Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F Activity
Shilpa Singh, Catherine E. Gleason, Min Fang, Yasmin Nabil Laimon, Vishal Khivansara, Shanhai Xie, Yavuz T. Durmaz, Aniruddha Sarkar, Kenneth H. Ngo, Varunika Savla, Yixiang Li, Muhannad Abu‐Remaileh, Xinyue Li, Marie-Anaïs Locquet, Bishma Tuladhar, , Matthew G. Oser
This paper develops cyclin A/B macrocyclic inhibitors that induce apoptosis in cancers with high E2F activity by blocking RxL-mediated interactions, showing efficacy in SCLC models.
Journal of Thoracic Oncology · Aug 1, 2025Peer-reviewedCancer Biology